Type 2 diabetes patients who are being treated with Invokana (canagliflozin) or other sodium-glucose cotransporter-2 (SGLT2) inhibitors may be at risk for ketoacidosis, a dangerous condition that occurs when the body produces high levels of ketones. Also known as diabetic ketoacidosis (DKA), ketosis or acidosis, this condition can result in a diabetic coma hospitalization, and even death.
In May 2015, the U.S. Food & Drug Administration (FDA) announced it was reviewing a possible link between Invokana and ketoacidosis, after at least 20 people taking SGLT2 inhibitors had been diagnosed with the disorder. In addition to Invokana, the FDA’s review also included:
The FDA’s review will determine whether new warnings or information should be added to the labeling of Invokana and other SGLT 2 inhibitors regarding a potential association with this dangerous condition.
The body produces ketones when it begins to burn fat for energy. In diabetes patients, this can occur when the body is unable to use glucose as an energy source due to a lack of insulin. Excessive levels of ketones can poison the body and lead to the development of diabetic ketoacidosis (DKA).
According to the FDA, at least 20 people using Invokana or other SGLT2 inhibitors required emergency treatment or were hospitalized for acidosis (reported as diabetic ketoacidosis (DKA), ketoacidosis, or ketosis) from March 2013 to June 6, 2014. Since then the agency has continued to receive additional reports of DKA and ketoacidosis in patients treated with SGLT2 inhibitors.
The FDA’s May 2015 alert noted that the reports of ketoacidosis associated with SGLT2 inhibitors were unusual, in that the condition is more likely to affect Type 1 diabetics. Invokana and other SGLT2 inhibitors are only approved to treat Type 2 diabetes. What’s more, blood sugar levels, when reported, were only slightly increased. According to the FDA, acidosis is generally accompanied by high blood sugar levels.
Symptoms of Invokana ketoacidosis condition may include:
While it completes is Invokana safety review, the FDA is advising those treated with SGLT2 inhibitors to seek medical attention if they experience symptoms that may be associated with ketoacidosis. Health care professionals should evaluate such patients for acidosis, including ketoacidosis, and discontinue treatment with the drugs if the diagnosis is confirmed.
You may be entitled to compensation for medical bills, lost wages, pain and suffering, and other damages if you were hospitalized with ketoacidosis while taking Invokana or another SGLT2 inhibitor. To learn more about filing an Invokana ketoacidosis lawsuit, please contact the nationwide law firm of Bernstein Liebhard LLP today. Free, no obligation case reviews can be obtained by calling .